Sangamo Therapeutics (NASDAQ:SGMO) Now Covered by StockNews.com

StockNews.com started coverage on shares of Sangamo Therapeutics (NASDAQ:SGMO – Free Report) in a research note released on Saturday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Several other research firms have also issued reports on SGMO. HC Wainwright restated a buy rating and set a $5.00 price target (up previously […]

Related Keywords

United States ,Canada , ,Mackenzie Financial Corp ,Sangamo Therapeutics Inc ,Royal Bank ,Sangamo Therapeutics Company Profile ,Miracle Mile Advisors ,Sg Americas Securities ,Vanguard Personalized Indexing Management ,Sangamo Therapeutics ,Free Report ,Get Free Report ,Mile Advisors ,Personalized Indexing Management ,Financial Corp ,Golden State Equity Partners ,State Equity Partners ,Sangamo Therapeutics Daily ,Nasdaq Sgmo ,Sgmo ,Medical ,80067710 ,Initiated Coverage ,Stocknews Com ,